Evaluation of protective efficacy of the synthetic peptide vaccine containing the T-helper 1 epitope with CpG oligodeoxynucleotide against feline infectious peritonitis virus infection in cats

Antiviral Therapy

Volumn 19, Issue 7, 2014, Pages 645-650

  Takano, Tomomi ^a   Tomizawa, Keisuke ^a   Morioka, Hiroyuki ^a   Doki, Tomoyoshi ^a   Hohdatsu, Tsutomu ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; NUCLEOCAPSID PROTEIN; NUCLEOCAPSID PROTEIN 7; NUCLEOCAPSID PROTEIN 8; PEPTIDE VACCINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; CPG-OLIGONUCLEOTIDE; EPITOPE; OLIGODEOXYRIBONUCLEOTIDE; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CELL FUNCTION; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONAVIRUS; DRUG SYNTHESIS; EPITOPE MAPPING; FELINE INFECTIOUS PERITONITIS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SURVIVAL RATE; TH1 CELL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS STRAIN; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; FELINE CORONAVIRUS; IMMUNOLOGY; MOLECULAR GENETICS; MONONUCLEAR CELL; MORTALITY;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; CATS; CORONAVIRUS, FELINE; EPITOPES, T-LYMPHOCYTE; FELINE INFECTIOUS PERITONITIS; IMMUNIZATION; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; NUCLEOCAPSID PROTEINS; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; VACCINES, SUBUNIT;

EID: 84920124334     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2735     Document Type: Article

References (20)

1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348:1953-1966.
2. Reusken CB, Haagmans BL, Müller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013; 13:859-866.
3. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg 2009; 11:225-258.
4. Petersen NC, Boyle JF. Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res 1980; 41:868-876.
5. Weiss RC, Scott FW. Antibody-dependent enhancement of disease in feline infectious peritonitis virus: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 1981; 4:175-189.
6. Kiss I, Poland AM, Pedersen NC. Disease outcome and cytokine responses in cats immunized with an avirulent feline infectious peritonitis virus (FIPV)-UCD1 and challenge-exposed with virulent FIPV-UCD-8. J Feline Med Surg 2004; 6:89-97.
7. Weiss RC, Cox NR. Delayed-type hypersensitivity skin response associated with feline infectious peritonitis in two cats. Res Vet Sci 1988; 44:396-398.
8. Hohdatsu T, Yamato H, Ohkawa T, et al. Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP. Vet Microbiol 2003; 97:31-44.
9. Liu J, Sun Y, Qi J, et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 2010; 202:1171-1180.
10. Satoh R, Furukawa T, Kotake M, et al. Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus. Vaccine 2011; 29:1791-1800.
11. Satoh R, Kotake M, Takano T, et al. Identification of cytosine-phosphorothioate-guanine oligodeoxynucleotide sequences that induce interferon-g production in feline immune cells. Microbiol Immunol 2011; 55:184-190.
12. Satoh R, Kaku A, Satomura M, et al. Development of monoclonal antibodies (MAbs) to feline interferon (fIFN)-g as tools to evaluate cellular immune responses to feline infectious peritonitis virus (FIPV). J Feline Med Surg 2011; 13:427-435.
13. Aichele P, Brduscha-Riem K, Oehen S, et al . Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 1997; 6: 519-529.
14. Miconnet I, Koenig S, Speiser D, et al. CpG are efficient adjuvants for specific CTL induction against tumor antigenderived peptide. J Immunol 2002; 168:1212-1218.
15. Speiser DE, Liénard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:739-746.
16. Chen M, Sällberg M, Hughes J, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005; 79:3016-3027.
17. Garza KM, Chan SM, Suri R, et al. Role of antigenpresenting cells in mediating tolerance and autoimmunity. J Exp Med 2000; 191:2021-2027.
18. Getts DR, Martin AJ, McCarthy DP, et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 2012; 30:1217-1224.
19. Geary SM, Lemke CD, Lubaroff DM, et al. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol Immunother 2011; 60:1309-1317.
20. Vermeulen BL, Devriendt B, Olyslaegers DA, et al. Suppression of NK cells and regulatory T lymphocytes in cats naturally infected with feline infectious peritonitis virus. Vet Microbiol 2013; 164:46-59.